This review reports that hair analysis can confirm drug exposure but not accurately estimate doses due to variability and confounding factors like melanin and cosmetic treatments, suggesting it should be used as a qualitative forensic tool rather than for precise dose quantification.
This review discusses the use of different biological samples, including hair, for drugtesting and highlights the complexities and considerations involved in interpreting results; it reports no new findings.
This study found that organoid cultures of human epithelial and mesenchymal cells can produce hair peg-like structures, and their growth is enhanced by minoxidil, suggesting potential for hairdrug screening.
Kopexil (Aminexil) is not approved as a drug in the US and Europe because it is marketed as a cosmetic, which requires less testing and regulation. L'Oreal's 1.5% Aminexil is noted to reduce hair shedding, but its efficacy as a drug is not proven.
An arthritis drug restored significant hair in people with alopecia areata, but it is not effective for male pattern baldness. The drug, Upadacitinib, has serious side effects and is expensive.
PP405 may reactivate dormant hair follicles but won't replace hair transplants or resurrect dead follicles. Its effectiveness, cost, and impact compared to treatments like minoxidil and finasteride are uncertain.
Finasteride users may have an increased risk of depression, anxiety, and suicidal thoughts, though some attribute these issues to hair loss itself. The link between finasteride and mental health effects is debated, with varying user experiences.
ABS-201, a prolactin receptor blocker, shows promise in reversing hair loss and graying, with early success in macaques. Current treatments like finasteride, minoxidil, and RU58841 are still widely used, but new options like PP405 are eagerly anticipated.
From hypertension to hair: the unexpected story of minoxidilMinoxidil was developed as an oral blood-pressure drug and approved as Loniten in 1979; unwanted hair growth in patients led to topical Rogaine, approved for men in 1988 and for women in 1991. Trials support topical minoxidil for pattern hair loss, while low-dose oral minoxidil is a prescription drug used off-label and needs medical supervision.
Can stemoxydine help improve hair density in both men and women?Stemoxydine is a cosmetic ingredient, not an approved hair loss drug, and the manufacturer's three-month trials enrolled men only, reporting a small increase in measured hair density. One small uncontrolled study that included women reported improvement in both sexes but more in men, so a benefit for women is not established.